Houston startup Collide secures $5M to grow energy-focused AI platform

Fresh Funds

Houston-based Collide plans to use its seed funding to accelerate the development of its GenAI platform for the energy industry. Photo via Getty Images

Houston-based Collide, a provider of generative artificial intelligence for the energy sector, has raised $5 million in seed funding led by Houston’s Mercury Fund.

Other investors in the seed round include Bryan Sheffield, founder of Austin-based Parsley Energy, which was acquired by Dallas-based Pioneer Natural Resources in 2021; Billy Quinn, founder and managing partner of Dallas-based private equity firm Pearl Energy Investments; and David Albin, co-founder and former managing partner of Dallas-based private equity firm NGP Capital Partners.

“(Collide) co-founders Collin McLelland and Chuck Yates bring a unique understanding of the oil and gas industry,” Blair Garrou, managing partner at Mercury, said in a news release. “Their backgrounds, combined with Collide’s proprietary knowledge base, create a significant and strategic moat for the platform.”

Collide, founded in 2022, says the funding will enable the company to accelerate the development of its GenAI platform. GenAI creates digital content such as images, videos, text, and music.

Originally launched by Houston media organization Digital Wildcatters as “a professional network and digital community for technical discussions and knowledge sharing,” the company says it will now shift its focus to rolling out its enterprise-level, AI-enabled solution.

Collide explains that its platform gathers and synthesizes data from trusted sources to deliver industry insights for oil and gas professionals. Unlike platforms such as OpenAI, Perplexity, and Microsoft Copilot, Collide’s platform “uniquely accesses a comprehensive, industry-specific knowledge base, including technical papers, internal processes, and a curated Q&A database tailored to energy professionals,” the company said.

Collide says its approximately 6,000 platform users span 122 countries.

---

This story originally appeared on our sister site, EnergyCapitalHTX.com.

The two entities will combine resources and efforts to "drive innovation, accelerate growth and empower young companies." Photo via Getty Images

2 Houston organizations team up to drive SaaS innovation within energy sector

howdy, partner

Two entities looking to support software-as-a-service innovation have teamed up on a new resource to meet the energy sector corporate clients' growing technology demands.

MOIC Partners, an energy enterprise software sales support solution provider founded earlier this year, and Venture Builder VC, a consulting firm, investor, and accelerator program operator led by a group of Houston innovators, have announced a new partnership. The two entities will combine resources and efforts to "drive innovation, accelerate growth and empower young companies," per a news release from the organizations.

“Throughout our careers, we’ve encountered various approaches to achieving the broader innovation objectives of Venture Builder VC and, in our judgment, this program truly stands out as a model that has the potential to introduce significant innovation to the energy sector in an abbreviated timeframe,” Dave Levitt of MOIC Partners says in the release.

MOIC Partners provides go-to-market products and services, including MOIC Sales Engine, MOIC Pipeline Grader, MOIC Pricing Engine, Virtual Dave, and MOIC Exit Engine.

Venture Builder VC recently partnered with NOV on a custom accelerator for the energy leader.

“We deliver disruptive solutions to enterprise R&D and innovation leaders by targeting growth-stage startups solving their specific problems," Billy Grandy, founder and general partner of Venture Builder VC, says in the release. "While founder-led models excel in driving change, they often struggle with scalability and change management with corporate customers. Our partnership with MOIC Partners provides essential tools to help small and mid-sized SaaS companies overcome these challenges and achieve sustainable growth.”

UH has named a new C-level exec to its Energy Transition Institute and entered into a new offshore partnership. Photo via UH.edu

University of Houston names new executive, partnership amid energy transition

go coogs

The University of Houston has made two big moves in growing its role in supporting the Houston energy transition.

UH to explore repurposing offshore tech for clean energy with new partnership

The two companies will work closely with UH's Repurposing Offshore Infrastructure for Clean Energy Project Collaborative, or the ROICE project. Photo via UH.edu

The University of Houston has signed a memorandum of understanding with two Houston-based companies that aims to repurpose offshore infrastructure for the energy transition.

The partnership with Promethean Energy and Endeavor Management ensures that the two companies will work closely with UH's Repurposing Offshore Infrastructure for Clean Energy Project Collaborative, or the ROICE project. The collaborative is supported by about 40 institutions to address the economic and technical challenges behind repurposing offshore wells, according to a statement from UH. It's funded in part by the Department of the Treasury through the State of Texas.

“These MOUs formalize our mutual commitment to advance the industry's implementation of energy transition strategies,” Ram Seetharam, Energy Center officer and ROICE program lead, said in the statement. “Together, we aim to create impactful solutions that will benefit both the energy sector and society as a whole.” Continue reading this story on EnergyCapital.

University of Houston names new energy transition-focused executive

Debalina Sengupta has been named as the chief operating officer of UH's Energy Transition Institute. Photo via UH.edu

The University of Houston has named a new C-level executive to its energy transition-focused initiative.

Debalina Sengupta has been named as the chief operating officer of UH's Energy Transition Institute, which was established in 2022 by a $10 million commitment from Shell USA Inc. and Shell Global Solutions (US) Inc. The institute focuses on hydrogen, carbon management and circular plastics and works closely with UH’s Hewlett Packard Enterprise Data Science Institute and researchers across the university.

Sengupta, who was previously a chemical engineer with over 18 years of experience with sustainability and resilience issues, was called to ETI’s mission and its focus on Houston, which is home to more than 4,500 energy companies and a pivotal international oil and gas hub.

“UH Energy Transition Institute is the first of its kind Institute setup in Texas that focuses solely on the transition of energy,” she says in a news release. “A two-way communication between the academic community and various stakeholders is necessary to implement the transition and I saw the UH ETI role enabling me to achieve this critical goal.” Continue reading this story on EnergyCapital.

------

These articles originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings